Royalty Pharma $2 billion senior notes offering
We advised Royalty Pharma on its investment-grade notes offering
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Elevance Health $3 billion senior notes offering
The investment-grade notes are due 2028, 2032, 2036 and 2055
Alnylam Pharmaceuticals $661.25 million convertible senior notes offering
The 0% convertible notes are due 2028
Maze Therapeutics $150 million private placement
The PIPE included common stock and pre-funded warrants
Merck $6 billion notes offering
The investment-grade notes offering consists of six tranches
Bruker mandatory convertible preferred stock offering
The preferred stock will be listed on Nasdaq
Precigen $125 million financing
We advised Precigen on the loan agreement
Ascletis HK$861.98 million placement of shares and top-up subscription
We advised the placing agent on the placement and the top-up subscription
Cardinal Health $1 billion notes offering
The investment-grade notes are due 2030 and 2035
Eli Lilly $6.75 billion notes offering
The investment-grade offering consisted of seven tranches